Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

13.6K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
13.6K
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.6K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

87
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
87
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

3.3K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.3K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

4.3K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Baseline Mismatch Negativity Amplitude Predicts Direction and Magnitude of Ketamine Effect in Healthy Volunteers: A Disordinal Effect.

Biological psychiatry·2026
Same author

Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.

Nature medicine·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Plasma biomarkers in neuropsychiatric syndromes: A narrative review.

Journal of Alzheimer's disease : JAD·2025
Same author

Beyond Alzheimer's disease-translating biomarker insights across CNS diseases.

Science translational medicine·2025
Same author

The GREENBEAN checklist for reporting studies evaluating the effectiveness of EEG-based biomarkers.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2025

Related Experiment Video

Updated: Apr 19, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.4K

Optimizing early Go/No Go decisions in CNS drug development.

William Z Potter1

  • 1National Institute of Mental Health, Bethesda, MD.

Expert Review of Clinical Pharmacology
|December 25, 2014
PubMed
Summary

Deciding whether to advance new central nervous system (CNS) drugs is challenging. A new strategy requires human data showing target engagement and functional effects before expensive efficacy studies.

Keywords:
CNS drug developmentGo/No Go decisionsRDoCbrain target engagementmechanistic hypotheses

More Related Videos

A Method for Remotely Silencing Neural Activity in Rodents During Discrete Phases of Learning
09:22

A Method for Remotely Silencing Neural Activity in Rodents During Discrete Phases of Learning

Published on: June 22, 2015

15.1K
Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

805

Related Experiment Videos

Last Updated: Apr 19, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.4K
A Method for Remotely Silencing Neural Activity in Rodents During Discrete Phases of Learning
09:22

A Method for Remotely Silencing Neural Activity in Rodents During Discrete Phases of Learning

Published on: June 22, 2015

15.1K
Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

805

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Development

Background:

  • Central nervous system (CNS) drug development faces significant challenges due to numerous molecular targets and limited therapeutic advances.
  • Costly clinical trials often fail to provide interpretable results on the therapeutic potential of pursued mechanisms.
  • Current decision-making processes for CNS compounds are problematic, leading to substantial investment without clear validation.

Discussion:

  • A new strategy mandates compelling human evidence of target engagement and CNS functional consequences before efficacy studies.
  • This approach aims to validate molecular hypotheses of drug action early in development.
  • Focusing on target engagement and functional outcomes can accelerate the identification of promising CNS drug candidates.

Key Insights:

  • Early human data on target engagement and functional effects are crucial for CNS drug development.
  • Testing molecular hypotheses in humans prior to extensive trials can improve decision-making.
  • This strategy enhances the efficiency of ruling out ineffective therapeutic mechanisms.

Outlook:

  • This refined decision-making process can improve the success rate of CNS drug development.
  • Further research is needed to address the limitations of predictive models for novel CNS drug efficacy.
  • Continued validation of molecular targets and mechanisms in humans is essential for future therapeutic breakthroughs.